NCT07358611Recruiting
Non-invasive Mapping-Guided Atrial Fibrillation Ablation
ELectrocardiographic Imaging-guided Substrate Ablation in Patients With Atrial Fibrillation - a PILOT Study of a Personalized Therapy
Source: ClinicalTrials.gov · Last updated 8 Jul 2026
Brief summary (registry, in English)
The goal of this pilot study is to test if noninvasive global mapping can guide catheter ablation defining personalized targets and improve the therapy of atrial fibrillation. It will also test the safety of such an approach. The main questions it aims to answer are: * Does ablation of targets defined by noninvasive global mapping improve rates of acute atrial fibrillation termination? * Does such a personalized ablation approach reduce arrhythmia recurrence rates? Researchers will compare the results of the personalized ablation approach with comparable patients that had undergone a conventional "empirical" ablation approach (pulmonary vein isolation). Participants will: * Undergo a personalized catheter ablation approach employing both a noninvasive global mapping system and a conventional intracardiac mapping system * Visit the clinic 3, 6 and 12 months after ablation for clinical follow-up * Schedule a telephone visit 9 and 24 months after ablation for clinical follow-up
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 14 Jan 2026
- Start date
- 31 Jan 2026
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Hospital Clinic of Barcelona
- Diseases
- Atrial fibrillation
- NCT number
- NCT07358611
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 31 Jan 2026 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous cardiac ablation
- Previous stroke/TIA
Other illness
- Dermal disease or hypersensitivity predisposing for skin irritation or exanthema
Lab values
- Severe left ventricular dysfunction (LVEF \<35%)
- Renal failure (GFR \<30 ml/min)
Age
- Age \<18 years
Other
- Pregnancy or lactation
Who the study is looking for
- Ablation-naïve patients with:
- Persistent AF planned for catheter ablation plus
- Left atrial enlargement (LA diameter ≥45 mm or LA volume index ≥35ml/m2 or LA area ≥20 cm2)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Clinic, University of Barcelona Coordinator of this site? Confirm its status | Barcelona | Spain | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.